| CAS NO: | 130663-39-7 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| Molecular Weight (MW) | 508.61 |
|---|---|
| Formula | C31H32N4O3 |
| CAS No. | 130663-39-7 (free base); |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 100 mg/mL (196.6 mM) |
| Water: 100 mg/mL (196.6 mM) | |
| Ethanol: 100 mg/mL (196.6 mM) | |
| Solubility (In vivo) | Saline: 30 mg/mL |
| Synonyms | PD 123319; PD-123319; PD123319 |
| In Vitro | In vitro activity: PD 123319 is shown to discriminate between two subclasses of AII receptors in many different tissues. 125I-AII specifically labeled two classes of binding sites for AII in a membrane preparation of bovine adrenal glomerulosa cells. The first class (DuP-753 sensitive) represents approximately 85% of the total binding sites for AII and possesses a high affinity (IC50 of 92.9 nM) for DuP-753. PD-123319 does not have any effect on 125I-AII binding to this site. The second class of binding sites is more sensitive to PD-123319, with an IC50 of 6.9 nM, and has a much lower affinity for DuP-753 (IC50 around 10 μM). Cell Assay: PD123319 suppressed osteogenic differentiation of human mesenchymal stem cells through inhibition of extracellular signal-regulated kinase signaling. |
|---|---|
| In Vivo | PD 123319 has no effect on cerebral blood flow autoregulation. Acute AT2-receptor blockade does not influence CBF autoregulation. Intravenous administration of PD 123319 to conscious hypertensive rats elicites an immediate dose-dependent increase in MAP that is sustained for approximately 7.4 min with 3 mg/kg PD 123319. |
| Animal model | Spontaneously hypertensive rats |
| Formulation & Dosage | Dissolved in saline; 0.36 and 1 mg/kg/min; i.v. injection |
| References | Mol Pharmacol. 1992 Apr;41(4):809-15; J Renin Angiotensin Aldosterone Syst. 2001 Sep;2(3):188-92. |
m.cnreagent.com